Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
March 13, 2014
The RegMed rodeo sponsors bronc riding and steer roping
March 12, 2014
Clouds gather over the RegMed sector, but no big storm just yet
March 11, 2014
Speculative froth continues
March 10, 2014
RegMed is caught in the vortices of flowing markets
March 7, 2014
The kickstand on the RegMed bike broke
March 7, 2014
Medistem (OTCQB: MEDS); Intrexon (NYSE: XON) Completes Acquisition
February 26, 2014
Follow the shorts
February 24, 2014
Flirtation or a short-term fixation
February 24, 2014
What’s the first thing to look for when entering a trade, the sell button?
February 21, 2014
The buying of RegMed which is not doing or saying anything unless you pay for it
35 companies, 1 interpreter!
Insight, foresight and recommendation
SOLD to Intrexon (NYSE: XON). MEDS stockholders will receive $0.27 in cash and $1.08 worth of XON’s common stock, based on the 20-day volume-weighted average price of the stock immediately prior to closing. MEDS platform has been saved; having NOT being able to raise capital – having been on a “thin” string for a while - it was the only “play or option” left!
goneMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors